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Abstract 
A four-year-old, neutered male Golden Retriever was presented with a one-week history 
of weight loss, polyuria and polydipsia. The diagnostic workup showed an increased 
ionized calcium concentration, mild increase in serum creatinine and urea concentration, 
and severe hyperlipasemia. A complete abdominal ultrasound revealed multiple hepatic 
nodules. A cytological diagnosis of malignant epithelial neoplasia, highly suggestive of 
bile duct adenocarcinoma was made. In order to confirm the presumptive diagnosis of 
hypercalcemia of malignancy due to the presence of a hepatic neoplasia, serum 
parathormone-related peptide concentration (PTH-rP) was measured, and the result 
revealed an increased concentration. The dog was hospitalized and received supportive 
treatments consisting of intravenous furosemide and fluid therapy. After ruling out 
lymphoma and hypoadrenocorticism, oral prednisone was initiated, and ionized calcium 
concentration decreased gradually down to normal concentration after seven days of 
hospitalization. Chemotherapy with intravenous epirubicin was initiated based on the 
cytological diagnosis. One month after diagnosis, and due to the worsening of its 
clinical condition, the dog was humanely euthanized. Post-mortem examination 
confirmed a cholangiocellular carcinoma. To our knowledge, this is the first report of 
malignant hypercalcemia associated with cholangiocellular carcinoma in a dog.  
 
Keywords: canine; neoplasia; liver; parathyroid hormone-related protein; ionized 
calcium 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
3 
 
Introduction 
Hepatobiliary neoplasia is uncommon in dogs and cats and accounts for less than 1.5% 
of all canine and 1% to 2.9% of all feline tumors. [1]  
Bile duct carcinoma or cholangiocellular carcinoma is the second most common hepatic 
tumor in dogs, followed by hepatocellular carcinoma, accounting for 22% to 41% of all 
malignant liver tumors in this species. [1] Bile duct carcinoma has an aggressive 
biologic behavior. Metastasis is common, particularly to regional lymph nodes and the 
lungs [1] with median survival times usually being less than six months. [2]  
The most frequent underlying cause of hypercalcemia in dogs is neoplasia. [3] A variety 
of tumors have been associated with hypercalcemia of malignancy in dogs, the two 
most common of which are lymphoma and apocrine gland adenocarcinoma of the anal 
sac. [3] However, hypercalcemia of malignancy has been documented with other tumors 
such as multiple myeloma, thyroid carcinoma, thymoma, squamous cells carcinoma, 
mammary gland carcinoma/adenocarcinoma, melanoma, primary lung tumors, chronic 
lymphocytic leukemia, renal angiomyxoma, and parathyroid gland tumors. [3,4] 
There is lack of information in the veterinary literature regarding malignancy–related 
hypercalcemia associated with hepatic tumors in dogs. The case presented here 
describes a case of hypercalcemia of malignancy associated with cholangiocellular 
carcinoma in a dog.  
Case presentation 
A four-year-old, neutered male Golden Retriever was presented for a one-week history 
of anorexia, polyuria, polydipsia, and weight loss.  
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On presentation, the dog was depressed and dehydrated, and a IV/VI grade heart 
murmur was ausculted. The remainder of the physical exam including rectal 
examination, was otherwise unremarkable.  
Minimal data base evaluation at presentation revealed a markedly increased ionized 
calcium concentration (2.73 mmol/L; reference interval 1.25 – 1.5). Initially, the dog 
received fluid therapy (sodium chloride 0.9%; B. Braun Medical, VetCare SA, Rubí, 
Barcelona) and treatment with intravenous furosemide (2 mg/kg BID; Seguril 
20mg/2mL Sanofi-Aventis SA, Barcelona). 
Clinical laboratory tests performed prior to referral included a complete blood cell 
count, serum biochemistry panel and urinalysis. Significant findings included an 
inflammatory leukogram, consisting of mild neutrophilia (15,392 neutrophils/µL; 
reference interval 2,940 – 12,670), with a left shift (187 bands/µL; reference interval 0 – 
170), marked total hypercalcemia (16.0 mg/dL; reference interval 8.2 – 11.9), severe 
hyperlipasemia (15,557 IU/L; reference interval 75 – 784, spectrophotometric method at 
37ºC), mild azotemia (serum creatinine 1.6 mg/dL; reference interval 0.5 – 1.5, and 
serum urea of 70 mg/dL; reference interval 21.4 – 59.9), mild hyperbilirubinemia (0.34 
mg/dL; reference interval 0.01 – 0.31), and a mild increase in AST activity (113 IU/L; 
reference interval 16 – 89). Phosphorus concentration was in the lower reference limit 
(2.7 mg/dL; reference interval 2.7 – 6.7).  Urinalysis performed on a urine sample 
obtained by cystocentesis revealed isosthenuria (urine specific gravity 1.008). Analysis 
using urine dipstick and urine sediment examination were unremarkable.  
Because lymphoma and hypoadrenocorticism are potential causes of hypercalcemia in 
dogs, thoracic radiographs, abdominal ultrasound and ACTH stimulation test were 
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performed. The results of the ACTH stimulation test were unremarkable, ruling out 
hypoadrenocorticism in this dog.  
Thoracic radiographs showed, on the ventrodorsal projection, an increase of cardiac 
silhouette cranial to the right atrium; whereas the laterolateral projection revealed an 
increased opacity at the dorsocranial level of the cardiac silhouette without tracheal 
displacement. The main differential diagnosis related to these findings were cardiac 
valvular disease or, less likely, neoplasia; a cardiac ultrasound was recommended but 
declined by the owners.  
An abdominal ultrasound revealed a mild amount of abdominal fluid and multiple 
hepatic nodules of heterogeneous echogenicity, with moderately defined margins and 
variable size, ranging from 0.8 to 3.5 cm (Fig 1). Mild mesenteric lymphadenomegaly 
was also identified. Neither renal calcification nor other remarkable findings were 
observed. Ultrasound-guided fine needle aspirates were obtained from the hepatic 
nodules for cytological evaluation and stained with the Quick Panoptic® stain (Fig 2) 
(Química Clínica Aplicada, Amposta, Spain). A cytological diagnosis of malignant 
epithelial neoplasia, highly suggestive of bile duct adenocarcinoma, with mild 
neutrophilic inflammation and hepatic cholestasis was made. A metastatic 
adenocarcinoma from a primary extrahepatic tumor or hepatic carcinoma were also 
considered as differentials. Hepatic biopsy with histopathological examination was 
recommended but the owners declined further investigations.  
Hypercalcemia of malignancy was suspected due to the presence of a hepatic neoplasm. 
In order to confirm the presumptive diagnosis, serum parathormone-related protein 
(PTH-rP) concentration was measured and was found to be increased (5 pmol/L, 
reference value < 2 pmol/L). Serum pre- and post-bile acids concentration were also 
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measured to evaluate liver function, in order to modify the chemotherapy dosage or 
protocol in case the liver function was impaired. The results of bile acid stimulation test 
revealed normal liver function. 
Initially, supportive treatment consisted of intravenous furosemide (2 mg/kg BID; 
Seguril 20mg/2mL Sanofi-Aventis SA, Barcelona) and fluid therapy (sodium chloride 
0.9%; B. Braun Medical, VetCare SA, Rubí, Barcelona). This did not decrease the 
ionized calcium concentration. The initial azotemia also worsened over the first 24h in 
hospital despite fluid therapy (serum creatinine 2.06 mg/dL; reference interval 0.5 – 1.5, 
and serum urea 95.7 mg/dL; reference interval 21.4 – 59.9).  
After ruling out lymphoma and hypoadrenocorticism, oral prednisone treatment 
(1mg/kg SID; Dacortin 30 mg, Merck S.L, Madrid) was initiated. Oral prednisone and 
intravenous furosemide were administered simultaneously during the first 3 days of 
hospitalization and ionized calcium concentrations decreased steadily from 2.73 
mmol/L to 2.02 mmol/L (reference interval 1.25 – 1.5). Due to this improvement, oral 
prednisone was continued but furosemide treatment was ceased. After 7 days of 
hospitalization, ionized calcium concentration returned to normal (1.47 mmol/L; 
reference interval 1.25 – 1.5), and the dog’s general condition improved. Further 
aggressive treatment, such as administration of bisphosphonates, sodium bicarbonate, 
calcium channel blockers or dialysis, were not deemed necessary given the 
improvement.   
Based on the cytological diagnosis, chemotherapy with intravenous epirubicin was 
started at day seven of hospitalization (30 mg/m
2
; Accord, 2mg/mL Injectable Solution, 
epirubicin hydrochloride, Accord Healthcare SA, Barcelona) and prescribed every three 
weeks for four sessions. Additional chemotherapy, using a metronomic protocol and 
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including piroxicam (0.3 mg/kg SID) and cyclophosphamide (10mg/m
2
 SID) was 
planned at week three after epirubicin treatment. 
The dog was discharged from the hospital with oral prednisone (1mg/kg SID, Dacortin 
30 mg, Merck S.L, Madrid). As the dog developed gastrointestinal signs during 
hospitalization (e.g. vomiting and diarrhea), treatment with metronidazole (7.5mg/kg 
BID, Flagyl 250 mg tablets, Sanofi-Aventis SA, Barcelona), maropitant (1mg/kg SID, 
Cerenia 60mg tablets, Zoetis Belgium, Louvain-la-Neuve, Belgium) and omeprazole 
(1mg/kg SID, Omeprazol Normon 40mg, S.A, Tres Cantos, Madrid) were also 
prescribed. The dog was also started on a prescription hepatic diet (Royal Canin® 
Hepatic). 
One week after being discharged, the ionized calcium was mildly elevated (1.58 
mmol/L; reference interval 1.25 – 1.50) and serum creatinine and urea were within 
normal limits; although in the upper reference limit (1.5 mg/dL; reference interval 0.5 –
1.5; and 58.2 mg/dL; reference interval 21.4 – 59.9, respectively). Ten days after the last 
examination, the dog returned with a 4 day history of vomiting, diarrhea and 
generalized weakness. At that time, ionized calcium was markedly increased (2.4 
mmol/L; reference interval 1.25 – 1.50). Due to the poor prognosis and clinical 
progression, the owners elected for euthanasia.  
On post-mortem examination, 5mL of serosanguinous peritoneal fluid was collected. 
The liver was enlarged with multiple, pale color and firm hepatic nodules of variable 
size, ranging from 0.5 to 5cm, with typical umbilicate appearance. The heart showed 
mild mitral valve thickening.  
Tissue samples from the lungs, spleen, kidney, normal liver parenchyma, hepatic 
nodules, myocardium, adrenal glands, stomach, intestine, pancreas, bone marrow, brain 
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and cerebellum were obtained and fixed in 10% neutral buffered formalin, paraffin 
embedded, and routinely processed for histologic examination. Sections (4µm) were 
stained with hematoxylin and eosin (HE). Histological sections of the hepatic nodules 
revealed multiple sites of local invasion of hepatic parenchyma by neoplastic epithelial 
cells (Fig 3 and Fig 4). Further assessment was performed to confirm the suspicious of 
cholangiocellular carcinoma. Periodic acid Schiff (PAS) staining of the liver’s 
histological section was positive (Fig 5). The kidneys showed marked mineralization, 
principally affecting the epithelium of cortical tubules, producing degeneration and loss 
of normal epithelium architecture. The stomach glandular epithelium showed a small 
amount of mineralization. Examination of the hypophysis of the pituitary revealed a 
small sized cystic lesion (2mm) containing basophilic acellular material. There was no 
evidence of metastasis to the regional lymph nodes or distant organs. 
Based on the histological findings and PAS stain, the final diagnosis was an intrahepatic 
cholangiocellular carcinoma, with renal tubular mineralization and a pituitary cyst.  
To determine if neoplastic cells from cholangiocellular carcinoma secreted PTH-rP, 
immunohistochemistry (IHC) for PTH-rP was performed at the Ohio State University 
College of Veterinary Medicine. Histologic sections (4µm) were deparaffinized, 
hydrated and pretreated in target retrieval solution (Dako, Santa Clara, CA, USA). 
Sections were incubated with primary anti-PTH-rP antibody for 30 minutes (Dako, 
Santa Clara, CA, USA, diluted 1:100), rinsed and incubated with biotinylated rabbit 
anti-goat antibody (Vector Laboratories, Burlingame, CA, USA, diluted 1:200) in 
protein block for 30 minutes. After rinsed, sections were incubated with Vector RTU 
ABC Elite complex (Vector Laboratories, Burlingame, CA, USA) for 30 minutes. The 
chromogen used for color development was 3,3’ diaminobenzidine tetrahydrochloride 
(DAB) (Dako, Santa Clara, CA, USA). Finally, sections were counterstained with 
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hematoxylin. For the negative control, sections were incubated with goat IgG for 30 
minutes (Vector Laboratories, Burlingame, CA, USA, diluted 1:100). Thyroid follicular 
carcinoma served as positive control. The cholangiocellular carcinoma exhibited 
minimal, nonspecific background staining leading to a negative result.  
Discussion 
This is to our best knowledge, the first case report of malignant hypercalcemia that 
could be associated with cholangiocellular carcinoma in a dog. Several case reports in 
human medicine have described hypercalcemia of malignancy associated with 
cholangiocellular carcinoma. [5,6,7,8,9] In people, cholangiocellular carcinoma has a 
poor prognosis but the tumor is rarely associated with a paraneoplastic syndrome. The 
prognosis for patients with cholangiocellular carcinoma that produces PTH-rP is even 
worse, where the interval between the diagnosis of hypercalcemia and the patient’s 
death is usually less than one year. [7]  
The increased PTH-rP concentration was considered the most likely cause of 
hypercalcemia in the dog described in this report; however, PTH-rP concentration was 
only mildly increased in this case as compared to other reports of canine hypercalcemia 
of malignancy induced by PTH-rP [10, 11]. In these previous reports, PTH-rP 
concentration was markedly increased, being 15.3 pmol/L (reference value < 2pmol/L) 
[10] and 21 pmol/L (reference value < 2pmol/L) [11]. This could suggest that PTH-rP 
might have be the main factor responsible for the induction of hypercalcemia in this 
dog. Several mechanisms of hypercalcemia of malignancy have been described in 
human and veterinary medicine include humoral hypercalcemia of malignancy due to 
circulating tumor-produced hormones or cytokines, and hypercalcemia resulting from 
primary bone tumors or metastases with local osteolytic bone resorption. [3, 12] The 
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negative result of the IHC for PTH-rP could suggest additional factors secreted by 
neoplastic cells that may have a synergistic or additive effect with PTH-rP. [3, 12] 
Additional factors could include osteoclast stimulatory factors, such as interleukin 1 and 
6, tumor necrosis factor-α, granulocyte-macrophage colony stimulating factor, 
macrophage colony stimulating factor, transforming growth factor-β, calcitriol, and 
macrophage inflammatory protein-1α. [12] Unfortunately, IHC or plasma tests for 
additional cytokines or calcitriol were not performed in this case.  
Although the neoplastic cells in the present case did not exhibit IHC positivity for PTH-
rP, they could contain PTH-rP messenger RNA, as occurs in humoral hypercalcemia of 
malignancy in dogs with anal sac adenocarcinoma where neoplastic cells stain weakly 
positive for PTH-rP but have abundant PTH-rP mRNA. [13] Unfortunately, PTH-rP 
mRNA expression was not analyzed in this dog. Furthermore, the body was frozen for 
36-48hr before post-mortem examination was performed, thus leading to tissue 
autolysis. Although post-mortem interval for at least 24h does maintain protein stability 
and IHC staining intensity for certain classes of antigens; careful interpretation of 
autolyzed material would be necessary since some proteins may degrade and lose 
detectable staining. [14] For that reason, the length of time before post-mortem 
examination in our case could have affected the IHC for PTH-rP. Furthermore, 
neoplastic cells may up-regulate and down-regulate gene expression, resulting in the 
absence of expression of expected antigens or the expression of new antigens. [15] 
A definitive diagnosis of intrahepatic cholangiocellular carcinoma was made by 
histopathology. Since histological morphology of cholangiocellular carcinoma and 
carcinoids might be similar, hepatic carcinoid could not be completely ruled out as a 
diagnosis. The presence of acini, tubules, intraluminal secretion and mucin are common 
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features of cholangiocellular carcinoma. Mucin was demonstrated with PAS stain and is 
common in cholangiocellular carcinomas but is not a feature of carcinoids. [16] 
Renal failure can result in hypercalcemia and may have been a contributing factor in 
this case. The urine specific gravity, azotemia and histologic evidence of renal 
pathology strongly indicated renal disease in this case. However, hypercalcemia was not 
considered to be secondary to renal disease. Dogs with chronic renal failure have 
usually normal to low ionized calcium concentration. [15]
 
The increased serum PTH-rP 
concentration was consistent with hypercalcemia of malignancy, and the evidence of 
renal tubular mineralization strongly indicates that hypercalcemia was the primary cause 
of the renal pathology.  
The biochemistry profile revealed a marked increase in serum pancreatic lipase activity 
with minimal simultaneous increase in serum amylase activity. This finding has been 
described in dogs with pancreatic and hepatic tumors. [17] The study published by 
Quigley et al., (2001) concluded that marked and unexplained hyperlipasemia may be 
used as a biochemical marker for pancreatic and hepatic epithelial malignant neoplasia 
in dogs. [17] Another consideration for the increase in serum pancreatic lipase activity 
in this dog was pancreatitis, since the serum biochemistry results and clinical findings 
(e.g. hyperbilirubinemia, hypercalcemia, weakness, gastrointestinal signs, polyuria and 
polydipsia) could be related to acute pancreatitis. Although hypocalcemia is most 
commonly associated with acute pancreatitis in dogs and cats [18], previous studies 
published in humans [19] and cats [20] have suggested that hypercalcemia induces 
pancreatic injury by increasing the permeability of the pancreatic duct to molecules such 
as pancreatic enzymes, followed by the accumulation and activation of proteases that 
results into pancreatitis. It is well known that serum lipase and amylase activities are not 
useful and should not be used for detection of pancreatic disease due to their low 
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sensitivity and specificity [21]. Another condition associated with increased lipase 
and/or amylase activities is renal disease, although renal disease was not considered in 
this case, since hyperlipasemia was severe. Other situations associated with 
hyperlipasemia are hepatic, intestinal, neoplastic diseases and corticosteroid 
administration [21]. The post-mortem examination did not reveal pancreatic disease. 
Histopathology is considered the gold standard for the diagnosis of pancreatitis [21]. 
However, exclusion of pancreatitis based on histopathology can be difficult since the 
inflammatory lesions are often focal and can be easily missed. In the present case, 
multiple sections of the pancreas were evaluated, increasing the likelihood of detection 
of microscopic lesions, and precluding the diagnosis of pancreatitis or pancreatic 
neoplasia in this dog.  
The liver function parameters, including bile acids, were within normal limits, 
suggesting that liver function was preserved; however, the dog exhibited mild 
hyperbilirubinemia most likely associated with hepatic and post-hepatic causes, 
secondary to cholangiocellular carcinoma and hepatic cholestasis.   
Post-mortem examination did not reveal any neoplasia other than the cholangiocellular 
carcinoma. Although the IHC could not confirm the expression of PTH-rP on neoplastic 
cells, the absence of other neoplasia or diseases suggest that the increase in serum PTH-
rP is most likely associated with cholangiocellular carcinoma.  
Conclusion 
This is, to our knowledge, the first case report of malignant hypercalcemia associated 
with cholangiocellular carcinoma in a dog. A differential diagnosis of cholangiocellular 
carcinoma should be included in dogs affected by hypercalcemia of malignancy of 
unknown origin. 
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Figure Legends 
Fig. 1. Abdominal ultrasound from a dog with cholangiocellular carcinoma and 
hypercalcemia of malignancy showing a hepatic nodule of heterogenous echogenicity 
(arrow). A small amount of abdominal effusion is noted (*). GB (gall bladder).  
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Fig. 2. Fine needle aspirate from the hepatic nodule of a dog with cholangiocellular 
carcinoma and hypercalcemia of malignancy. Small epithelial cells (10 to 12 µm) with 
round to cuboidal morphology, mostly individually organized or in small clusters with 
acinar arrangement, occasionally containing grey amorphous material are noted. The 
epithelial cells display an elevated nucleus: cytoplasm ratio, with mild anisocytosis and 
anisokaryosis. Binucleated (arrowhead) and multinucleated cells (arrow) are observed. 
Quick Panoptic Stain
®
.  
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Fig. 3. Histological section of the cholangiocellular carcinoma from the patient in this 
report. Multiple sites of local invasion of surrounding hepatic parenchyma by neoplastic 
cells are noted. Tumor cells proliferated in a multifocal to coalescent, multilobulated, 
and encapsulated nodules. Hematoxylin and Eosin stain.  
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Fig. 4. Histological section of the cholangiocellular carcinoma described in this report. 
Medium sized neoplastic epithelial cells with cuboidal to columnar morphology, with 
small amount of eosinophilic cytoplasm and discrete margins are observed. The 
neoplastic epithelial cells form well-differentiated ductal and acini structures, 
occasionally with eosinophilic to weakly basophilic secretory material within the lumen, 
suggestive of mucin, and separated by fibrous connective-tissue stroma. Hematoxylin 
and Eosin stain.  
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Fig. 5. Histological section of the cholangiocellular carcinoma described in this report. 
Positive Periodic acid Schiff (PAS) stain confirms the mucin nature of the secretory 
material (arrow), a common feature of cholangiocellular carcinoma. Hematoxylin and 
Eosin and PAS stain.  
 
 
